<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156139</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZX09201013</org_study_id>
    <nct_id>NCT04156139</nct_id>
  </id_info>
  <brief_title>HFNC vs NPPV After Early Extubation for Patients With COPD</brief_title>
  <official_title>High-flow Nasal Cannula Versus Noninvasive Positive Pressure Ventilation Therapy After Early Extubation for Patients With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-flow nasal cannula oxygen therapy(HFNC) has proved no significant difference compared
      with noninvasive positive pressure ventilation (NPPV) in preventing postextubation
      respiratory failure and reintubation in patients with acute hypoxemic respiratory
      failure.However, the efficacy of early postextubation sequential HFNC in COPD patients with
      hypercapnic respiratory failure is inconclusive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators conducted this prospective randomized controlled trial to explore the
      efficacy, safety of HFNC versus NPPV after early extubation in COPD patients with hypercapnic
      respiratory failure.The investigators hypothesized that the efficacy of HFNC after early
      extubation is non-inferior to that of NPPV.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reintubation</measure>
    <time_frame>within the 7 days after extubation.</time_frame>
    <description>The primary outcome is reintubation within the 7 days after extubation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weaning failure</measure>
    <time_frame>within the7 days after extubation</time_frame>
    <description>Secondary Outcome is a composite criterion including reintubation events or all-cause deaths within the7 days after extubation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">502</enrollment>
  <condition>COPD</condition>
  <condition>Hypercapnic Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NPPV treatment for patients will be performed for patients immediately after extubation in control group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HFNC treatment will be performed for patients immediately after extubation in the intervention group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HFNC</intervention_name>
    <description>The gas flow rate was set at 45~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NPPV</intervention_name>
    <description>The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. COPD patients with bronchopulmonary infection 2. Patients with hypercapnia
             respiratory failure treated with invasive mechanical 3.14 days ≥ invasive mechanical
             ventilation ≥ 48 hours; 4.Reached the pulmonary infection control (PIC) window; 5.Have
             self-care ability with oxygen supply during stable phrase

        Exclusion Criteria:

          -  Severe organ dysfunction;Myopathy or myasthenia gravis;Upper airway obstruction;A
             large amount of secretions and inability to drain;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>XIE Lixin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Han Xiaobo, MD</last_name>
    <phone>+86 18600310765</phone>
    <email>hansir510@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cao jiang, MD</last_name>
      <phone>+86 010-66937166</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Lixin Xie</investigator_full_name>
    <investigator_title>Director of Department of Respiratory and Critical Care Medicine, Chinese PLA General Hospital</investigator_title>
  </responsible_party>
  <keyword>NPPV</keyword>
  <keyword>HFNC</keyword>
  <keyword>Weaning</keyword>
  <keyword>COPD</keyword>
  <keyword>PIC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

